Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 12

1.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN.

PLoS One. 2011 Feb 16;6(2):e17103. doi: 10.1371/journal.pone.0017103.

2.

A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.

Ray A, Mann MK, Basu S, Dittel BN.

J Neuroimmunol. 2011 Jan;230(1-2):1-9. doi: 10.1016/j.jneuroim.2010.10.037. Epub 2010 Dec 10. Review.

3.

Monoclonal antibody-induced inhibition of relapsing EAE in SJL/J mice correlates with inhibition of neuroantigen-specific cell-mediated immune responses.

Kennedy MK, Clatch RJ, Dal Canto MC, Trotter JL, Miller SD.

J Neuroimmunol. 1987 Nov;16(3):345-64. Review.

PMID:
2444626
4.

Green tea EGCG, T cells, and T cell-mediated autoimmune diseases.

Wu D, Wang J, Pae M, Meydani SN.

Mol Aspects Med. 2012 Feb;33(1):107-18. doi: 10.1016/j.mam.2011.10.001. Epub 2011 Oct 14. Review.

PMID:
22020144
5.

T cell receptor peptide therapy for autoimmune disease.

Vandenbark AA, Chou YK, Bourdette DN, Whitham R, Hashim GA, Offner H.

J Autoimmun. 1992 Apr;5 Suppl A:83-92. Review.

PMID:
1503638
6.

MASTering the immune response: mast cells in autoimmunity.

Gregory GD, Bickford A, Robbie-Ryan M, Tanzola M, Brown MA.

Novartis Found Symp. 2005;271:215-25; discussion 225-31. Review.

PMID:
16605138
7.

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Racke MK, Lovett-Racke AE.

J Immunol. 2011 Feb 15;186(4):1887-90. doi: 10.4049/jimmunol.1090138. Review.

8.

[B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].

Kondo S, Akashi T, Katsuta H, Iwakiri R, Anzai K, Nagafuchi S, Niho Y, Harada M.

Fukuoka Igaku Zasshi. 2005 Apr;96(4):86-92. Review. Japanese.

PMID:
15991605
9.

Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.

Shetty S, Ahmed AR.

Autoimmunity. 2013 Dec;46(8):487-96. doi: 10.3109/08916934.2013.838563. Epub 2013 Oct 24. Review.

PMID:
24151854
10.

CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?

Pateinakis P, Pyrpasopoulou A.

Biomed Res Int. 2014;2014:973609. doi: 10.1155/2014/973609. Epub 2014 Mar 27. Review.

11.

Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials.

Bonnan M, Ferrari S, Bertandeau E, Demasles S, Krim E, Miquel M, Barroso B.

Curr Drug Targets. 2014;15(13):1205-14. Review.

PMID:
25355180
12.

The Role of Latently Infected B Cells in CNS Autoimmunity.

Márquez AC, Horwitz MS.

Front Immunol. 2015 Oct 28;6:544. doi: 10.3389/fimmu.2015.00544. eCollection 2015. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk